Beta Andrenergic Receptor Structure and Desensitization
Beta Andrenergic Receptor Structure and Desensitization
批准号:
7937878
负责人:
RICHARD B CLARK
金额:
$41.09万
依托单位国家:
美国
项目类别:
财政年份:
1983
资助国家:
美国
项目状态:
已结题
起止时间:
1983-04-01 至 2012-08-31
关键词:
AddressAdrenergic ReceptorAgonistAntibodiesAreaArrestinsAsthmaAttentionBindingBiological AssayBiological ModelsBronchodilationBronchodilator AgentsCardiovascular DiseasesCatalytic DomainCell LineCell modelCellsChronicComplexCoupledCyclic AMPCyclic AMP-Dependent Protein KinasesDevelopmentDiseaseDown-RegulationEffectivenessEventExcisionFeedbackFluorescence Resonance Energy TransferG Protein-Coupled Receptor Kinase FamilyG protein coupled receptor kinaseG-Protein-Coupled ReceptorsGRK5 geneGoalsHormonesHumanHydrolysisInflammationKineticsKnowledgeLeadLigandsMediatingMediationMembraneMethodologyModelingMolecularMutagenesisNaturePathway interactionsPeptide LibraryPeptidesPharmaceutical PreparationsPhosphorylationPhysiologicalPlayProcessProgress ReportsProtein DephosphorylationReceptor ActivationReceptor SignalingRegulationRelative (related person)RhodopsinRoleSecond Messenger SystemsSignal TransductionSimulateSiteSmooth Muscle MyocytesSteroidsStimulusStructureSystemSystems BiologyTestingTimebasedesensitizationdesignfightinggene therapyimprovedinhibitor/antagonistmembermimeticsmimicrymodels and simulationmutantoverexpressionphosphoric diester hydrolasereceptorreconstitutionrespiratory smooth muscleresponsesecond messenger
中文摘要
132-肾上腺素能受体(132 AR)在“战或逃”反应中起主要作用
包括支气管扩张的调节。用受体激动剂引起支气管扩张
132 AR与类固醇一起沿着用于治疗炎症,是慢性哮喘的主要治疗方法。
已知支气管扩张剂的有效性随时间降低(脱敏),
因此,132 AR的激动剂脱敏的表征一直是
许多研究的焦点,从这些研究中得出的证据使它成为一个
G蛋白偶联受体(GPCR)的研究范式。但不少
关于脱敏的分子机制仍然存在问题,
重要的是132 AR信号复合物如何在去除
刺激.在系统生物学水平上,需要对系统生物学进行动态建模。
复杂的抑制性反馈环,涉及PKA和多个132 AR磷酸化
G蛋白偶联受体激酶(GRK)亚型及其下游后遗症
例如抑制蛋白结合、内化和磷酸二酯酶的活化。以来
大多数132 AR脱敏研究都是用细胞系进行的
由于132 AR过表达,因此需要研究原发性肝癌的脱敏作用。
表达内源水平的132 AR的人细胞。另一方面,
脱敏抑制剂的开发很少受到关注。我们
该小组在132 AR三个领域的持续研究中取得了重大进展
脱敏过程;表征GRKs的GPCR活化,
GRK活性抑制剂的面板,以及脱敏和
再敏化,导致以下具体目标:(1)表征132 AR
HASM和模型细胞系统中的脱敏,重点是定量
控制132 AR功效和
第二信使cAMP通过磷酸二酯酶的下游作用
(2)确定132 AR激活GRKs的机制
受体和相关的GPCR视紫红质通过详细的结构/功能研究,
进化上重要的GRK残基;(3)肽抑制剂的开发
基于对重要GRK的了解,
和132个AR结构域参与相互作用。
英文摘要
The 132-adrenergic receptor (132AR) plays a major role in the "fight-or-flight" response
including mediation of bronchodilation. Eliciting bronchodilation with agonists of the
132AR is, along with steroids to treat inflammation, a major treatment of chronic asthma.
The effectiveness of the bronchodilators is known to decrease over time (desensitize),
and as such the characterization of agonist desensitization of the 132AR has been the
focus of a multitude of studies, and the evidence derived from these has made it a
paradigm for the study of G protein coupled receptors (GPCRs). However, many
questions remain concerning the molecular mechanisms of desensitization, and
importantly. how the 132AR signaling complex resensitizes following removal of
stimulation. At the systems biology level, there is a need for a dynamic modeling of the
complex inhibitory feedback loops involving 132AR phosphorylation by PKA and multiple
G protein coupled receptor kinase (GRK) subtypes, and their downstream sequelae
such as arrestin binding, internalization, and activation of phosphodiesterase. Since
most studies of 132AR desensitization have been performed with cell lines
overexpressing the 132AR, there is a need for studies of desensitization in primary
human cells expressing endogenous levels of the 132AR. Another aspect that has
received little attention has been the development of inhibitors of desensitization. Our
group has made significant inroads in ongoing studies of three areas of the 132AR
desensitization process; characterization of GPCR activation of GRKs, development of a
panel of inhibitors of GRK activity, and systems modeling of desensitization and
resensitization, leading to the following specific aims: (1) characterization of 132AR
desensitization in both HASM and model cell systems with a focus on quantitative
systems modeling of the processes that control loss of both 132AR efficacy and
downstream actions of the second messenger cAMP through phosphodiesterase
hydrolysis; (2) determination of the mechanism of activation of GRKs by the 132AR
receptor and the related GPCR rhodopsin through detailed structure/function studies of
evolutionarily important GRK residues; and (3) development of peptide inhibitors
that disrupt the GPCRlGRK interaction based on knowledge gained of important GRK
and 132AR domains involved in the interaction.
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Multiple non-specific effects of sphingosine on adenylate cyclase and cyclic AMP accumulation in S49 lymphoma cells preclude its use as a specific inhibitor of protein kinase C.
鞘氨醇对 S49 淋巴瘤细胞中腺苷酸环化酶和环 AMP 积累的多种非特异性影响使其无法用作蛋白激酶 C 的特异性抑制剂。
DOI:
10.1042/bj2680507
发表时间:
1990
期刊:
The Biochemical journal
影响因子:
--
作者:
[Johnson,JA, Clark,RB]
通讯作者:
Clark,RB
DOI:
10.1085/jgp.200709881
发表时间:
2008-04
期刊:
The Journal of general physiology
影响因子:
--
作者:
[Xin W, Tran TM, Richter W, Clark RB, Rich TC]
通讯作者:
Rich TC
Epinephrine-induced sequestration of the beta-adrenergic receptor in cultured S49 WT and cyc- lymphoma cells.
肾上腺素诱导培养的 S49 WT 和环淋巴瘤细胞中 β-肾上腺素能受体的隔离。
DOI:
--
发表时间:
1985
期刊:
Journal of cyclic nucleotide and protein phosphorylation research
影响因子:
--
作者:
[Clark,RB, Friedman,J, Prashad,N, Ruoho,AE]
通讯作者:
Ruoho,AE
Phosphatidate and monooleylphosphatidate inhibition of fibroblast adenylate cyclase is mediated by the inhibitory coupling protein, Ni.
成纤维细胞腺苷酸环化酶的磷脂酸和单油基磷脂酸抑制作用是由抑制性偶联蛋白 Ni 介导的。
DOI:
--
发表时间:
1985
期刊:
Molecular pharmacology
影响因子:
3.6
作者:
[Proll,MA, Clark,RB, Butcher,RW]
通讯作者:
Butcher,RW
DOI:
10.1021/bi700922h
发表时间:
2007-11
期刊:
Biochemistry
影响因子:
2.9
作者:
[T. Tran;Rasmus Jorgensen;R. B. Clark]
通讯作者:
T. Tran;Rasmus Jorgensen;R. B. Clark
共 17 条
SMALL INSTRUMENTATION GRANT
-
批准号:3524967
-
项目类别:
-
资助金额:$2.03万
-
财政年份:1992
-
负责人:RICHARD B CLARK
-
依托单位:
STRUCTURE/FUNCTION OF THE TSH RECEPTOR
-
批准号:3023297
-
项目类别:
-
资助金额:$2.23万
-
财政年份:1991
-
负责人:RICHARD B CLARK
-
依托单位:
SMALL INSTRUMENTATION PROGRAM
-
批准号:3524771
-
项目类别:
-
资助金额:$2.24万
-
财政年份:1989
-
负责人:RICHARD B CLARK
-
依托单位:
BETA-ADRENERGIC RECEPTOR STRUCTURE AND DESENSITIZATION
-
批准号:2684744
-
项目类别:
-
资助金额:$28.41万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
BETA-ADRENERGIC RECEPTOR STRUCTURE AND DESENSITIZATION
-
批准号:2900566
-
项目类别:
-
资助金额:$29.55万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
BETA-ADRENERGIC RECEPTOR STRUCTURE AND DESENSITIZATION
-
批准号:3279137
-
项目类别:
-
资助金额:$19.07万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
B-ADRENERGIC RECEPTOR STUCTURE & DESENSITIZATION
-
批准号:3279136
-
项目类别:
-
资助金额:$13.32万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
BETA-ADRENERGIC RECEPTOR STRUCTURE AND DESENSITIZATION
-
批准号:6606900
-
项目类别:
-
资助金额:$29.8万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
Beta Adrenergic Receptor Structure and Desensitization
-
批准号:6871479
-
项目类别:
-
资助金额:$32.74万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
B-ADRENERGIC RECEPTOR STUCTURE & DESENSITIZATION
-
批准号:3279141
-
项目类别:
-
资助金额:$17.83万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
B-ADRENERGIC RECEPTOR STUCTURE & DESENSITIZATION
-
批准号:3279142
-
项目类别:
-
资助金额:$16.17万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
BETA-ADRENERGIC RECEPTOR STRUCTURE AND DESENSITIZATION
-
批准号:6262609
-
项目类别:
-
资助金额:$29.9万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
BETA-ADRENERGIC RECEPTOR STRUCTURE AND DESENSITIZATION
-
批准号:2391915
-
项目类别:
-
资助金额:$27.32万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
Beta Adrenergic Receptor Structure and Desensitization
-
批准号:7169827
-
项目类别:
-
资助金额:$30.98万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
B-ADRENERGIC RECEPTOR STUCTURE & DESENSITIZATION
-
批准号:3279140
-
项目类别:
-
资助金额:$13.48万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
BETA-ADRENERGIC RECEPTOR STRUCTURE AND DESENSITIZATION
-
批准号:6286063
-
项目类别:
-
资助金额:$9.81万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
Beta Andrenergic Receptor Structure and Desensitization
-
批准号:7737553
-
项目类别:
-
资助金额:$42.41万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
BETA-ADRENERGIC RECEPTOR STRUCTURE AND DESENSITIZATION
-
批准号:2176048
-
项目类别:
-
资助金额:$21.02万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
BETA-ADRENERGIC RECEPTOR STRUCTURE AND DESENSITIZATION
-
批准号:2176049
-
项目类别:
-
资助金额:$21.67万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
B-ADRENERGIC RECEPTOR STRUCTURE AND DESENSITIZATION
-
批准号:3279138
-
项目类别:
-
资助金额:$8.3万
-
财政年份:1983
-
负责人:RICHARD B CLARK
-
依托单位:
海外基金